Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Advisory Committee Gives Thumbs Up To Chugai’s Actemra RA Treatment

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The U.S. FDA's Arthritis Advisory Committee voted 10 to one for approving Actemra (tocilizumab) a rheumatoid arthritis treatment that Japan's Chugai Pharmaceutical already is marketing for Castleman's disease, Chugai and partner Roche announced July 30
Advertisement

Related Content

Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown
Roche Pharma Japan General Manager and Asia Regional Head-Pharma Partnering Mark Noguchi In Hot Pursuit Of Sources Of Innovation in Asia: An Interview with PharmAsia News
Chugai’s Reduced Tamiflu Sales, Fallout From Sanofi-Aventis Deal Attribute To 35% Earnings Drop
Chugai’s Reduced Tamiflu Sales, Fallout From Sanofi-Aventis Deal Attribute To 35% Earnings Drop
Roche Pharma Japan General Manager and Asia Regional Head-Pharma Partnering Mark Noguchi In Hot Pursuit Of Sources Of Innovation in Asia: An Interview with PharmAsia News
Roche Partnership With Chugai Fuels Actemra Approvals In Japan, Sets Stage For U.S. And EU – Chugai Exec
Chugai Gets Japanese Approval For Actemra For Rheumatoid Arthritis
Advertisement
UsernamePublicRestriction

Register

SC069192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel